Norditropin Daily denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Imposes Quantity Limits on Norditropin

UnitedHealthcare applies quantity limit (QL) edits to somatropin products, including Norditropin, as a formulary utilization-management tool. A quantity-limits denial means that the prescribed supply or pen cartridge count exceeds the quantity that UHC's benefit system will automatically approve for the covered period. This is among the more common — and more straightforward — Norditropin denial types to appeal, particularly when the prescribed quantity is driven by the patient's weight-based dosing regimen or clinical circumstances.

## Why This Denial Is Appealable

Quantity limits are set by plan policy, but they are not always calibrated to individual patient need. Growth hormone therapy is weight-based — a patient's required quantity may legitimately exceed a default limit simply due to body size, or because a dose adjustment was recently made in response to clinical monitoring. When the prescribed quantity is directly supported by the patient's weight, clinical response data, and the prescribing physician's rationale, a quantity-limit exception is well-founded. UHC is required to consider exceptions based on medical necessity.

## Federal Appeal Framework

• Quantity-limit exception request: The first step — file a formal exception request before or alongside the internal appeal.
• Internal appeal: Under ERISA §503 and ACA §2719, any adverse determination (including QL denial) is subject to full-and-fair internal review.
• External review: If the internal appeal fails, independent external review by an IRO is available. File within the four-month external-review window from the denial date.
• Expedited review: Request expedited processing if the quantity limit will interrupt active therapy.

## Concrete Appeal Steps and Timeline

1. Confirm the exact quantity limit UHC applied (this must appear in the denial notice or be available from UHC member services). 2. Compare the approved quantity against the prescribed quantity and identify the precise shortfall. 3. Ask your prescriber to document in the medical record — and in the appeal letter — why the prescribed quantity is medically necessary (e.g., current weight and dosing calculation, response monitoring results, pen-cartridge concentration used). 4. File a QL exception request with UHC, attaching the prescriber documentation. 5. If denied, immediately file the internal appeal. 6. Escalate to external review if needed.

## Documentation to Gather

• Current weight and dosing rationale: A prescriber note or letter explaining how the prescribed quantity was calculated based on the patient's current weight and the dosing regimen consistent with the FDA label.
• Monitoring data: Recent labs (e.g., IGF-1 levels) and clinical notes showing therapeutic response and confirming that the current dose is appropriate.
• Pen concentration/device used: The specific Norditropin pen formulation and concentration, which affects how many cartridges or pens are needed per dosing period.
• Treatment history: Duration of therapy, any dose adjustments, and clinical outcomes to date.
• Prescriber medical-necessity letter: Explicitly stating that the prescribed quantity is medically necessary and cannot be reduced without clinical harm.

## Criteria-Mapping Structure

Obtain UHC's quantity-limit exception criteria from the denial notice or UHC's pharmacy benefit guidelines. Map each criterion:

| UHC QL Exception Criterion | Supporting Documentation | |---|---| | [Copy criterion verbatim from UHC policy or denial] | [Weight, lab value, prescriber calculation, or clinical note with date] |

Attach the prescriber's dosing rationale, the relevant labs, and the completed table. When the case for the prescribed quantity is clearly anchored in patient-specific clinical data, quantity-limit exceptions are frequently granted.